REWIND, DECLARE, and high-risk diabetes patients | diabetes.medicinematters.com

Medicine Matters Diabetes

Top

07-02-2019 | Dulaglutide | Podcast | Article

REWIND, DECLARE, and high-risk diabetes patients

LISTEN: How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti (9:04).

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Medicine Matters Diabetes

REWIND, DECLARE, and high-risk diabetes patients

Be confident that your patient care is up to date

Related content

Dulaglutide cardioprotective in relatively low-risk REWIND population

Expert commentary: A nurse educator’s view of the REWIND trial

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Round-up of the DPP-4 inhibitor CV outcome trials

Medicine Matters Diabetes

External Content

Be confident that your patient care is up to date

Related content

Dulaglutide cardioprotective in relatively low-risk REWIND population

Expert commentary: A nurse educator’s view of the REWIND trial

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Round-up of the DPP-4 inhibitor CV outcome trials